top of page
About
Technology
Vaccine Pipeline
News
Contact
More
Use tab to navigate through the menu items.
All Posts
Press Releases
In the News
Search
The Scientist: Nasal Vaccines Are Commercially High Risk, Perhaps High Reward
Jun 14, 2022
Bloomberg BusinessWeek: Why Nasal Sprays Are Poised to Be the Next Weapon for Fighting Covid
Apr 25, 2022
The Washington Post: The Next Leap in Coronavirus Vaccine Development Could Be a Nasal Spray
Apr 11, 2022
News Channel Nebraska: Hastings Doctor Leading ‘History-Making’ RSV Vaccine Trial
Mar 10, 2022
FierceBiotech: Meissa's Early Clinical Data on COVID-19 Vaccine Supports Transmission Blocking Role
Nov 2, 2021
Yahoo! News: A Nasal COVID-19 Vaccine Could Be the Solution to Ending the Pandemic, Experts Say
Oct 28, 2021
JAMA: Trying to Block SARS-CoV-2 Transmission With Intranasal Vaccines
Oct 14, 2021
BioPharm International: Meissa’s Intranasal COVID-19 Vaccine Yields Promising Preclinical Data
Jul 26, 2021
Science: Scent of a Vaccine
Jul 22, 2021
National Geographic: A Spritz Instead of a Jab? Future COVID-19 Vaccines May Go up Your Nose.
Jul 22, 2021
Reuters: Intranasal Vaccine Aims to Block Virus at Point of Entry
Jul 20, 2021
BioSpace: Meissa's Intranasal COVID-19 Vaccine Shows Promise in Non-Human Primates
Jul 19, 2021
MedCity News: Meissa Vaccines’ Leg up in the Covid-19 Vaccines Chase Goes through the Nose
Jul 19, 2021
Big4Bio Podcast: How a Long Effort to Protect Against RSV May Lead to a Better COVID-19 Vaccine
Jul 18, 2021
Big4Bio: Building Single Dose, Intranasal Vaccines to Prevent COVID-19 and RSV
Jul 11, 2021
Big4Bio: Meissa Vaccines Is Driven to Rid the World of Viral Respiratory Scourges
Jul 4, 2021
Biotech 2050 Podcast: An End Game Vaccine for COVID-19
May 24, 2021
BioSpace: Meissa’s Intranasal COVID-19 Vaccine Uses Codon Deoptimization for Stronger Responses
Mar 24, 2021
San Francisco Business Times: Covid Vaccine Player Hopes to Start Clinical Trial Early Next Year
Jul 30, 2020
BioSpace: Another COVID-19 Vaccine Joins the Race – This Time, it’s a Live, Weakened Virus
Jul 20, 2020
FierceBiotech: Meissa Raises $30M to Take RSV Vaccine into the Clinic
Sep 26, 2019
Xconomy: Meissa Scores $30M to Test Vaccine for Dangerous Respiratory Virus
Sep 26, 2019
Endpoints: Meissa Obtains $30M Series A to Test Synthetic Biology Approach to 'Elusive' RSV Vaccines
Sep 26, 2019
bottom of page
